Timing correction: Globe Life will release 2Q26 results after the market closes on Wednesday, July 22, 2026. The earnings call is Thursday, July 23, 2026, at 11:00 a.m. ET. Thus, results are due today, not tomorrow; the call is tomorrow.
Globe Life enters 2Q earnings with operating momentum, a meaningful capital-return program, and several favorable underwriting drivers. The key issue is not merely whether GL exceeds a quarterly EPS number; it is whether results validate the company’s full-year outlook and support the durability of its normalized earnings growth once the expected 3Q assumption-update gain is separated out.
The shares closed at $184.37 on July 21, up roughly 33% year to date, versus about 9.5% for the S&P 500 over the same period. At that price, GL trades at approximately 11.8x the midpoint of management’s $15.40–$15.90 2026 operating-EPS guidance. That is not an aggressive multiple in isolation, but the stock’s recent appreciation raises the bar for confirmation that:
This is probably the most important near-term operating datapoint.
In 1Q26, health premium grew 13% year over year to $417 million, while health underwriting margin grew 12% to $95 million, or 23% of premium. Management characterized that margin as seasonally normal for the first quarter, but explicitly expects total health underwriting margin to move above 25% in each of the remaining three quarters of 2026.
The primary driver is United American’s Medicare Supplement business. GL expects approximately $65 million of incremental 2026 premium from previously approved in-force rate increases, with most of that benefit occurring after 1Q. Management indicated that roughly $20 million per quarter of added premium should arrive in each of 2Q–4Q.
What investors should watch: - Total health underwriting margin above 25% of premium would support management’s full-year 23%–27% outlook. - United American’s margin is especially important: it was only 3% in 1Q, but management expects a roughly 10% average margin over the final three quarters. - Medicare Supplement sales growth and claims/utilization trends will determine whether rate actions translate cleanly into improved profitability.
Why it matters: A health-margin recovery would make the 2026 earnings algorithm more balanced and reduce concern that strong health sales are being purchased at lower returns.
American Income Life remains Globe Life’s largest life distribution channel. In 1Q, American Income life premium increased 5%, life underwriting margin rose 7%, and net life sales grew 3%. However, its average producing-agent count declined 4% year over year and 5% sequentially to 11,064.
Management attributed the decline principally to new-agent retention and said it changed middle-management compensation at the start of 2Q to emphasize recruiting and early-tenure retention. The company expects that initiative to help during the second half of the year.
What investors should watch: - The quarterly average producing-agent count at American Income. - Whether management reports an early improvement in recruiting pipelines or first-six-month agent retention. - Life net-sales growth relative to the “mid-single-digit” full-year expectation. - Whether agent productivity remains strong even if headcount recovery is delayed.
Read-through: Continued sales growth despite lower agent count demonstrates productivity resilience, but a prolonged decline in the field force would ultimately constrain premium growth and make the long-term growth story less compelling.
GL’s life business is the core earnings engine. In 1Q, life premium grew 3% and life underwriting margin was $349 million, or 41% of premium. Management expects the life margin to remain around 41% in both 2Q and 4Q.
The company’s favorable mortality experience is already embedded in its outlook. Management expects a $70 million–$110 million pre-tax benefit from annual life-assumption updates in 3Q26, implying an unusually high 3Q life underwriting margin of 49%–54%. That is a future-quarter event, so investors should not expect a comparable lift in 2Q.
What investors should watch: - Whether 2Q life margin holds near 41%. - Commentary on mortality, particularly heart/circulatory disease, cancer, and non-medical claims. - Lapse experience, which management expects to remain elevated versus pre-pandemic levels but broadly consistent with 2025. - Confirmation that the expected 3Q assumption-update benefit remains intact.
Key interpretation: A normal 2Q life margin near 41% is a positive outcome. A materially stronger figure could improve confidence in the 3Q reserve-assumption benefit; a weaker result would raise questions around mortality, lapses, or acquisition-cost amortization.
1Q sales momentum was strong: - Total life net sales: +6% - Total health net sales: +58% - United American health net sales: +122% to $62 million - Family Heritage health net sales: +22% - Liberty National life net sales: +13%
United American is benefiting from ongoing movement of consumers from Medicare Advantage toward Medicare Supplement plans. Management increased its 2026 United American health-sales outlook to high-teens growth, although it also cautioned that comparisons become much more difficult late in the year after exceptionally strong 2025 growth.
What investors should watch: - Whether United American’s sales growth remains robust without deterioration in underwriting quality. - Family Heritage agent-count growth and health-sales momentum. - Liberty National’s ability to sustain both agent growth and life-sales growth. - Direct-to-consumer conversion and lead-generation efficiency, where GL is increasing advertising spend after seeing improved agency conversion of shared leads.
Globe Life repurchased 1.4 million shares for $203 million in 1Q, at an average price of $141.24. It raised 2026 share-repurchase guidance to $560 million–$610 million, alongside approximately $90 million of shareholder dividends.
The buyback effect is meaningful: 1Q diluted weighted-average shares were 79.7 million, down from 84.5 million a year earlier. Even modest growth in underlying underwriting and investment income can translate into stronger per-share growth when paired with this level of repurchase activity.
Management expects $650 million–$700 million of 2026 parent excess cash flow and targets a consolidated RBC ratio of 300%–320%.
What investors should watch: - 2Q repurchase dollars, average purchase price, and diluted-share-count trajectory. - Any change in full-year capital-return guidance. - Parent liquidity and statutory-dividend commentary. - The status of GL’s Bermuda initiative and reciprocal-jurisdiction filing, which management had expected to update following 2Q.
A June refinancing also extended the credit-facility maturity to June 2031 and increased the term loan to $450 million from $250 million, with the term-loan maturity extended to June 2029. Investors should seek clarity on the intended use of the additional borrowing capacity and any implications for financing costs or capital flexibility.
| Metric | 2Q25 actual | 1Q26 actual | What to look for in 2Q26 |
|---|---|---|---|
| Net operating EPS | $3.27 | $3.43 | Continued double-digit per-share growth, aided by buybacks |
| Total premium | $1.218B | $1.270B | Progress toward ~7% full-year growth |
| Life premium growth | 3% | 3% | Consistency with 3%–3.5% full-year outlook |
| Health premium growth | 8% | 13% | Acceleration from Medicare Supplement rate increases |
| Life underwriting margin | $340M / 41% | $349M / 41% | Around 41%; no need for a reserve-related gain in 2Q |
| Health underwriting margin | $98M / 26% | $95M / 23% | Above 25% margin would validate the anticipated step-up |
| American Income agent count | 12,241 | 11,064 | Evidence that compensation changes are stabilizing recruitment/retention |
| Share repurchases | $226M | $203M | Pace toward $560M–$610M for the year |
Management’s current 2026 operating-EPS guidance is $15.40–$15.90, with a midpoint of $15.65, representing approximately 8% reported EPS growth. Importantly, the guidance includes the expected 3Q life-assumption benefit.
Management instead frames normalized EPS growth—excluding the assumption-update impacts in both 2025 and 2026—at approximately 11% at the midpoint. That normalized figure is likely the better measure of sustainable earnings power.
For 2Q, investors should focus on the underlying cadence rather than expect a one-time reserve gain: - Life: roughly stable margin near 41%. - Health: meaningful margin improvement from rate increases. - Investment income: continued modest growth, supported by reinvestment yields above portfolio yields. - Shares: a lower diluted count should remain an important EPS tailwind.
A constructive report would likely include: - Health margin above 25%, led by improvement at United American. - Life margin around or above the 41% normalized level. - Sustained strong Medicare Supplement sales without unfavorable claims trends. - Stabilization in American Income agent count or encouraging leading indicators. - Reaffirmed or increased operating-EPS and repurchase guidance. - Confirmation that the anticipated 3Q assumption-update benefit remains in the stated range. - Clear progress on Bermuda regulatory and capital-management plans.
The adverse setup would be: - Health margin remains near the 1Q 23% level despite expected rate-increase benefits. - Higher lapse rates or weaker agent retention pressure life sales. - American Income agent count continues to fall without evidence that 2Q compensation changes are working. - Medicare Supplement utilization or morbidity trends deteriorate. - Investment income or capital generation disappoints, limiting buybacks. - Guidance is maintained only because of the expected 3Q assumption gain while normalized earnings expectations weaken.
GL’s 2Q report is principally an underwriting-quality and execution test. The company has already established a favorable 2026 framework: stable life margins, improving health economics, high reinvestment yields, strong cash generation, and aggressive share repurchases. The stock’s outperformance means investors will likely demand proof that the health-margin step-up is underway and that American Income’s agent-count decline is temporary.
The most constructive outcome is not necessarily a large EPS beat. It is a report showing that health rate actions are flowing through, life margins remain durable around 41%, the agency model is stabilizing, and management can retain confidence in normalized double-digit EPS growth beyond the 3Q reserve-assumption benefit.
Sources reviewed: Globe Life 1Q26 earnings release and earnings-call transcript; Globe Life 2Q25 earnings release; Globe Life’s July 8, 2026 earnings-date announcement; Globe Life’s June 29, 2026 Form 8-K; historical GL and SPY closing-price data through July 21, 2026.